Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429762 · ClinicalTrials.gov registry record · Phase 1
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05429762 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 56 participants.
The verdict
NCT05429762, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a Phase1, single-arm study for treatment. This is a prospective multicenter, multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the Investigator, no standard alternative therapy is available.
Interventions
- DRUG Tusamitamab ravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2024-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05429762
The ClinicalTrials.gov registry entry for NCT05429762 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tusamitamab ravtansine is the first listed.
NCT05429762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05429762 about?
NCT05429762 is a clinical study titled "Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors". This is a Phase1, single-arm study for treatment. This is a prospective multicenter, multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastr...
What is the current status of trial NCT05429762?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-10-03. Estimated completion is 2024-04-10.
What interventions are being tested in trial NCT05429762?
The interventions under investigation include: Tusamitamab ravtansine (DRUG).
Who is sponsoring clinical trial NCT05429762?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.